KYNTRA BIO, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
KYNTRA BIO, INC. (KYNB) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $984.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-13
- KYNTRA BIO, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $984.00K, a 47.46% decline year-over-year.
- KYNTRA BIO, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $1.15M, a 59.64% decline year-over-year.
- KYNTRA BIO, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-12-31 was $1.19M, a 567.98% increase year-over-year.
- KYNTRA BIO, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $662.00K, a 91.39% decline year-over-year.
- KYNTRA BIO, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $6.58M, a 73.92% decline from fiscal 2024.
- KYNTRA BIO, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $25.21M, a 50.33% decline from fiscal 2023.
- KYNTRA BIO, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $50.77M, a 22.61% decline from fiscal 2022.
- KYNTRA BIO, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $65.60M, a 7.81% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $984.00K 10-Q · filed 2026-08-13 | $2.13M 10-Q · filed 2026-08-13 | $3.32M derived: sum of 3 quarters · filed 2026-08-13 | $3.99M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $1.15M 10-Q · filed 2026-05-12 | $2.34M derived: sum of 2 quarters · filed 2026-05-12 | $3.00M derived: sum of 3 quarters · filed 2026-05-12 | $4.88M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $1.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $1.85M derived: sum of 2 quarters · filed 2026-03-16 | $3.72M derived: sum of 3 quarters · filed 2026-08-13 | $6.58M 10-K · filed 2026-03-16 |
| 2025-09-30 | $662.00K 10-Q · filed 2025-11-10 | $2.54M derived: sum of 2 quarters · filed 2026-08-13 | $5.39M 10-Q · filed 2025-11-10 | $5.57M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $1.87M 10-Q · filed 2026-08-13 | $4.72M 10-Q · filed 2026-08-13 | $4.90M derived: sum of 3 quarters · filed 2026-08-13 | $12.59M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $2.85M 10-Q · filed 2026-05-12 | $3.03M derived: sum of 2 quarters · filed 2026-05-12 | $10.72M derived: sum of 3 quarters · filed 2026-05-12 | $19.30M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $178.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $7.87M derived: sum of 2 quarters · filed 2026-03-16 | $16.45M derived: sum of 3 quarters · filed 2026-03-16 | $25.21M 10-K · filed 2026-03-16 |
| 2024-09-30 | $7.69M 10-Q · filed 2025-11-10 | $16.27M derived: sum of 2 quarters · filed 2025-11-10 | $25.04M 10-Q · filed 2025-11-10 | $34.33M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $8.59M 10-Q · filed 2025-08-11 | $17.35M 10-Q · filed 2025-08-11 | $26.65M derived: sum of 3 quarters · filed 2025-08-11 | $36.12M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $8.76M 10-Q · filed 2025-05-12 | $18.06M derived: sum of 2 quarters · filed 2025-05-12 | $27.53M derived: sum of 3 quarters · filed 2025-05-12 | $43.42M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $9.30M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $18.77M derived: sum of 2 quarters · filed 2025-03-17 | $34.66M derived: sum of 3 quarters · filed 2025-03-17 | $50.77M 10-K · filed 2025-03-17 |
| 2023-09-30 | $9.48M 10-Q · filed 2024-11-12 | $25.36M derived: sum of 2 quarters · filed 2024-11-12 | $41.47M 10-Q · filed 2024-11-12 | $57.68M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $15.88M 10-Q · filed 2024-08-06 | $32.00M 10-Q · filed 2024-08-06 | $48.20M derived: sum of 3 quarters · filed 2024-08-06 | $63.79M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $16.11M 10-Q · filed 2024-05-06 | $32.32M derived: sum of 2 quarters · filed 2024-05-06 | $47.90M derived: sum of 3 quarters · filed 2024-05-06 | $64.56M derived: sum of 4 quarters · filed 2024-05-06 |
| 2022-12-31 | $16.21M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $31.79M derived: sum of 2 quarters · filed 2024-02-26 | $48.45M derived: sum of 3 quarters · filed 2024-02-26 | $65.60M 10-K · filed 2024-02-26 |
| 2022-09-30 | $15.59M 10-Q · filed 2023-11-06 | $32.24M derived: sum of 2 quarters · filed 2023-11-06 | $49.40M 10-Q · filed 2023-11-06 | $66.47M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-06-30 | $16.66M 10-Q · filed 2023-08-07 | $33.81M 10-Q · filed 2023-08-07 | $50.88M derived: sum of 3 quarters · filed 2024-02-26 | $66.59M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-03-31 | $17.15M 10-Q · filed 2023-05-08 | $34.22M derived: sum of 2 quarters · filed 2024-02-26 | $49.93M derived: sum of 3 quarters · filed 2024-02-26 | $68.93M derived: sum of 4 quarters · filed 2024-02-26 |
| 2021-12-31 | $17.07M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $32.78M derived: sum of 2 quarters · filed 2024-02-26 | $51.78M derived: sum of 3 quarters · filed 2024-02-26 | $71.16M 10-K · filed 2024-02-26 |
| 2021-09-30 | $15.70M 10-Q · filed 2022-11-07 | $34.70M derived: sum of 2 quarters · filed 2022-11-07 | $54.09M 10-Q · filed 2022-11-07 | $74.36M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $19.00M 10-Q · filed 2022-08-08 | $38.38M 10-Q · filed 2022-08-08 | $58.65M derived: sum of 3 quarters · filed 2023-02-27 | $76.55M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $19.38M 10-Q · filed 2022-05-09 | $39.65M derived: sum of 2 quarters · filed 2023-02-27 | $57.54M derived: sum of 3 quarters · filed 2023-02-27 | $75.19M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $20.27M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $38.16M derived: sum of 2 quarters · filed 2023-02-27 | $55.80M derived: sum of 3 quarters · filed 2023-02-27 | $72.72M 10-K · filed 2023-02-27 |
| 2020-09-30 | $17.89M 10-Q · filed 2021-11-09 | $35.53M derived: sum of 2 quarters · filed 2021-11-09 | $52.45M 10-Q · filed 2021-11-09 | $69.85M derived: sum of 4 quarters · filed 2022-03-04 |
| 2020-06-30 | $17.64M 10-Q · filed 2021-08-09 | $34.56M 10-Q · filed 2021-08-09 | $51.96M derived: sum of 3 quarters · filed 2022-03-04 | $66.75M derived: sum of 4 quarters · filed 2022-03-04 |
| 2020-03-31 | $16.92M 10-Q · filed 2021-05-10 | $34.32M derived: sum of 2 quarters · filed 2022-03-04 | $49.11M derived: sum of 3 quarters · filed 2022-03-04 | $66.75M derived: sum of 4 quarters · filed 2022-03-04 |
| 2019-12-31 | $17.40M derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-03-04 | $32.20M derived: sum of 2 quarters · filed 2022-03-04 | $49.84M derived: sum of 3 quarters · filed 2022-03-04 | $66.27M 10-K/A · filed 2022-03-04 |
| 2019-09-30 | $14.79M 10-Q · filed 2020-11-05 | $32.44M derived: sum of 2 quarters · filed 2020-11-05 | $48.87M 10-Q · filed 2020-11-05 | $62.58M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $17.64M 10-Q · filed 2020-08-06 | $34.07M 10-Q · filed 2020-08-06 | $47.78M derived: sum of 3 quarters · filed 2021-03-01 | $62.10M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $16.43M 10-Q · filed 2020-05-07 | $30.14M derived: sum of 2 quarters · filed 2021-03-01 | $44.46M derived: sum of 3 quarters · filed 2021-03-01 | $57.69M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | $13.71M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $28.03M derived: sum of 2 quarters · filed 2021-03-01 | $41.26M derived: sum of 3 quarters · filed 2021-03-01 | $52.14M 10-K · filed 2021-03-01 |
| 2018-09-30 | $14.32M 10-Q · filed 2019-11-12 | $27.55M derived: sum of 2 quarters · filed 2019-11-12 | $38.43M 10-Q · filed 2019-11-12 | |
| 2018-06-30 | $13.23M 10-Q · filed 2019-08-08 | $24.11M 10-Q · filed 2019-08-08 | ||
| 2018-03-31 | $10.88M 10-Q · filed 2019-05-09 | |||
| 2017-12-31 | $37.54M 10-K · filed 2020-03-02 | |||
| 2016-12-31 | $32.13M 10-K · filed 2019-02-27 | |||
| 2015-12-31 | $27.68M 10-K · filed 2018-02-27 | |||
| 2014-12-31 | $18.70M 10-K · filed 2017-03-01 | |||
| 2013-12-31 | $3.44M 10-K · filed 2016-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 |